Search Results
Your search for ,dUe matches 5406 pages
Showing 2151 - 2200Ringing a Bell on the Last Day of Radiation Therapy: Helpful or Harmful?
Some patients with cancer celebrate the end of a course of radiation or chemotherapy by ringing a bell. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them. However, a study published by Williams et al in the International Journal of Radiation...
Dual VEGF and PD-1 Inhibition in Advanced Solid Tumors
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Taylor et al found the combination of the VEGF inhibitor lenvatinib and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed activity across a range of advanced solid tumors. As stated by the authors, there is ...
How Real-World Data Can Help Contextualize New Treatments in Older Patients
Consider a patient who is referred for neoadjuvant therapy for stage IIIA, HER2-positive breast cancer. She is otherwise healthy, with no significant medical history, an Eastern Cooperative Oncology Group performance status of 0, unremarkable baseline labs, and a left-ventricular ejection fraction...
Expert Point of View: A. Jo Chien, MD
The formal discussant of this abstract on the ATEMPT trial, A. Jo Chien, MD, Associate Professor at UCSF’s Helen Diller Comprehensive Cancer Center, San Francisco, said that a median follow-up of 3-years is relatively short for this trial, considering about 75% of patients had hormone...
Cemiplimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
As reported in The Lancet Oncology by Migden et al, a phase II trial has shown activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. The trial supported the September 2018 U.S. Food and Drug Administration approval of cemiplimab in this setting. In this report, ...
Studies Find Estrogen Alone Protective, Estrogen Plus Progestin Detrimental in Postmenopausal Women
In postmenopausal women without prior breast cancer, estrogen alone reduced the risk of breast cancer, not only during treatment, but for years after estrogen was stopped. It also reduced deaths as a result of breast cancer and deaths after breast cancer from all causes. However, in contrast,...
Largest Single-Year Drop in Cancer Mortality Ever Reported: 2016–2017
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
Oral CC-486 Maintenance Therapy Extends Survival in Older Patients With AML
Use of CC-486—an investigational oral form of azacitidine—as maintenance therapy significantly improved overall survival and relapse-free survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following induction chemotherapy with or without consolidation ...
ADMIRAL Trial: More Than Standard Chemotherapy Needed for FLT3-Mutant Advanced AML
The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine1 and reviewed in this issue of The ASCO Post, shows the efficacy of a specific FLT3 inhibitor in patients with advanced acute myeloid leukemia (AML) and enhances the era of personalized medicine in leukemia. ...
First-Line Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer: Second Overall Survival Interim Analysis
As reported in The Lancet Oncology by Peter Schmid, MD, and colleagues, the prespecified second interim analysis of overall survival in the phase III IMpassion130 trial has shown no overall survival benefit with the addition of atezolizumab to nab-paclitaxel as first-line treatment of...
Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
On December 18, 2019, the antibody-drug conjugate enfortumab vedotin-ejfv (PadcevTM) was granted accelerated approval for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed cell death protein 1 (PD-1) or programmed cell...
Fam-trastuzumab Deruxtecan-nxki for Previously Treated Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, 2019, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was granted accelerated approval in the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2...
Breast Cancer Chemoprevention Effect Maintained Long After Stopping Anastrozole Therapy
For postmenopausal women at high risk for developing breast cancer—largely based on family history—anastrozole taken for 5 years maintained a preventive effect for at least an additional 7 years after stopping the drug in the IBIS-II trial, which included nearly 4,000 subjects. Women randomly...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma
In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma
A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL
Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...
Cancer Survivors Face Substantial Medical Financial Hardship
Although advances in cancer treatments have led to huge increases in the number of survivors in the United States—more than 16.9 million in 2019—many of those survivors, particularly those aged 18 to 64, face substantial medical financial hardship due to their diagnosis and treatment, necessitating ...
Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens including the monoclonal antibody daratumumab in combination ...
Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer May Have Different Rates of Mortality
New research indicates that there is a higher risk of early death among patients with oropharyngeal cancer not associated with human papillomavirus (HPV) vs those whose tumors are HPV-positive. The findings are published by Fullerton et al in Cancer. The incidence of oropharyngeal cancer is...
Activity of Belantamab Mafodotin in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In the phase II DREAMM-2 trial reported in The Lancet Oncology, Sagar Lonial, MD, and colleagues found that the antibody-drug conjugate belantamab mafodotin was active in patients with heavily pretreated relapsed or refractory multiple myeloma. The agent is a conjugate of an anti–B-cell maturation...
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
In the phase III MEDALIST trial reported in The New England Journal of Medicine, Fenaux et al found that luspatercept significantly reduced the severity of anemia vs placebo in red blood cell transfusion–dependent patients with very low- to intermediate-risk myelodysplastic syndromes with ring...
ADMIRAL Trial: Gilteritinib Improves Overall Survival in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Alexander E. Perl, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage...
Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies
A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies. This agent is designed to overcome several challenges inherent in CAR T-cell therapy, including CD19-antigen escape, which leads to relapse in ...
Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial
As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...
Largest Single-Year Drop in Cancer Mortality Reported in ‘Cancer Statistics, 2020’
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
Is Pembrolizumab Active in Pediatric Patients With PD-L1–Positive Advanced Solid Tumors or Lymphoma?
Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was...
Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention
As reported by Jack Cuzick, PhD, and colleagues in The Lancet, blinded follow-up of the IBIS-II trial has shown the continued benefit of anastrozole vs placebo in preventing breast cancer in high-risk postmenopausal women during the 5-year posttreatment period. For the international double-blind...
Saliva Test May Play A Role in the Early Detection of HPV-Related Oropharyngeal Cancer
A report by Wang et al in The Journal of Molecular Diagnostics described the use of acoustofluidics, a noninvasive method that analyzes saliva for the presence of human papillomavirus type 16 (HPV-16), the pathogenic strain of the disease associated with oropharyngeal cancers. This novel technique...
CMS Finalizes Updates to E&M Codes, Establishes MIPS Value Pathways
The Centers for Medicare & Medicaid Services (CMS) released its final rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B reimbursement policies, including proposals related to the Quality Payment Program (QPP). The estimated impact of the final MPFS...
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: KEYNOTE-013 and KEYNOTE-170
Findings in the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials, reported in the Journal of Clinical Oncology by Philippe Armand, MD, PhD, of DanaFarber Cancer Institute, and colleagues, indicate that pembrolizumab is active in relapsed or refractory primary mediastinal large B-cell...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting....
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
The Antiseptic Era: 1876–1900
The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era: 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photographs appear courtesy of Dr. Burns and The Burns Archive. To ...
Selected Abstracts From the 2019 ASH Annual Meeting & Exposition
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for acute myeloid leukemia (AML). For full details of these...
Coexisting With Cancer and Depression
Among the highlights at the 2019 Supportive Care in Oncology Symposium in October was the keynote address by Thomas J. Smith, MD, FACP, FASCO, FAAHPM, the Harry J. Duffey Family Professor of Palliative Medicine and Director of Palliative Medicine at Johns Hopkins Medicine and Professor of Oncology ...
ACCC Project Focuses on Multidisciplinary Care of Cutaneous Squamous Cell Carcinoma
Due to the rarity of advanced cutaneous squamous cell carcinoma, staying current with the latest information on diagnosing, treating, and supporting patients with this diagnosis can be challenging for clinicians who do not often encounter it in practice. To support the multi-disciplinary cancer...
Acupuncture May Reduce Radiation-Induced Dry Mouth for Patients With Head and Neck Cancer
After receiving acupuncture treatment 3 days a week during the course of radiation treatment, patients with head and neck cancer experienced less dry mouth, according to study results published by Garcia et al in JAMA Network Open. The results are from the first randomized, placebo-controlled,...
Acalabrutinib for Adult Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On November 21, 2019, the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib was approved for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The review resulting in approval was conducted under Project Orbis, an initiative of the U.S....
Expert Point of View: Sherene Loi, MD
Sherene Loi, MD, of Peter MacCallum Cancer Centre, Melbourne, Australia, said that the BROCADE3 trial was positive because it met its primary endpoint. However, she expressed some reservations about adopting this combination as a new standard for HER2-negative BRCA-mutated advanced breast cancer....
Veliparib/Chemotherapy Combination Active in HER2-Negative BRCA-Positive Advanced Breast Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin/paclitaxel chemotherapy significantly improved progression-free survival in patients with advanced HER2-negative breast cancer and germline BRCA mutation compared with placebo plus chemotherapy, according to...
First-Line Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer: Second Overall Survival Interim Analysis
As reported in The Lancet Oncology by Peter Schmid, MD, and colleagues, the prespecified second interim analysis of overall survival in the phase III IMpassion130 trial has shown no overall survival benefit with the addition of atezolizumab to nab-paclitaxel as first-line treatment of unresectable, ...
Immunotherapy for Head/Neck Squamous Cell Carcinoma: Questions Raised by KEYNOTE-048
There is a new first-line treatment option for patients with newly diagnosed, recurrent, or metastatic head and neck squamous cell carcinoma. As reported by Burtness et al in The Lancet, pembrolizumab improved overall survival vs the standard-of-care regimen of cetuximab and platinum-based...
ESMO Immuno-Oncology 2019: CXCR4 Inhibitor in Combination With Pembrolizumab/Chemotherapy for Metastatic Pancreatic Cancer
When the CXCR4 inhibitor BL-8040 was combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab plus chemotherapy in the second-line setting, the regimen showed promising antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma. These findings were...
ESMO Immuno-Oncology 2019: Sitravatinib/Tislelizumab Shows Antitumor Activity in Ovarian Cancer
Results from a phase Ib study reported at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 showed manageable safety and encouraging antitumor activity in patients with advanced ovarian cancer treated with the novel combination of sitravatinib and tislelizumab. These...
ACCC Project Focuses on Multidisciplinary Care of Cutaneous Squamous Cell Carcinoma
Due to the rarity of advanced cutaneous squamous cell carcinoma, staying current with the latest information on diagnosing, treating, and supporting patients with this diagnosis can be challenging for clinicians who do not often encounter it in practice. To support the multidisciplinary cancer team ...
